Practıcal Aspects of 68Ga-Labelled Dota-Peptides for Peptide-Receptor Radionuclide Therapy

Yıl 2016, , 149 - 155, 27.12.2016

Betül Taşdelen

https://doi.org/10.30931/jetas.297622

Öz

68Gallium-labeled receptor ligands, such as 68Gallium DOTATOC, 68Gallium-DOTANOC, and
68Gallium-DOTATATE which are used in PET are becoming gold standard of 68Ga-labeled peptides.
The 68Ga-labeled peptides show a rapid renal clearance and are rapidly accumulated in the tumors (80%
within 30 minutes); concentration in tissues without expression of somatostatin receptors is low,
providing higher contrast imaging. Here, this paper presents the practical aspects and the results of
preparation and radiolabelling DOTA-peptides with TiO2-based commercially available 68Ge/68Ga
generator by using fully automated radiopharmaceutical synthesis device. The radiochemical purity
(RCP) of 68Ga-labeled DOTA-peptides has been investigated using high performance liquid
chromatography (HPLC) and instant thin layer chromatography (ITLC). The labeling procedure resulted
in high radiochemical yield. The system allows the fully automated, efficient and rapid preparation of
68Ga-DOTA-derivatized peptides.

Anahtar Kelimeler

68Ga, DOTANOC, DOTATATE, peptides, PET

Kaynakça

• [1] Hayes RL, Carlton JE, Byrd BL., “Bone scanning with gallium-68 a carrier effect.” J. Nucl. Med. 6 (1965): 605-610.
• [2] Shealy, C.N., Aronow, S., Brownell, GL. “Gallium-68 as a scanning agent for intracranial lesions.” J. Nucl. Med. 5 (1964): 161-167.
• [3] Deutsch, E., “Clinical PET: its time has come?” J. Med. 3 (1993):1132-1133.
• [4] Rösch F., Knapp F.F. (Russ), Radionuclide Generators. in A Vértes, S Nagy, Z Klencsár, F Rösch (eds.), “Handbook of Nuclear Chemistry 4” Kluwer Academic Publishers, The Netherlands (2003): 81-118.
• [5] Hofmann, M., Maecke, H., Börner, A.R., Weckesser, E., Schöffski, P., Oei, M.L., Schumacher, J., Henze, M., Heppeler, A., Meyer, G.J. and Knapp, W.H., “Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data.” Eur. J. Nucl. Med. 28 (2001): 1751–1757.
• [6] Wild, D., Schmitt, J.S., Ginj, M., Macke, H.R., Bernard, B.F., Krenning, E., “DOTA NOC, a high- affinity ligand of somatostation receptor subtypes 2, 3 and 5 for labeling with various radiometals.” Eur. J. Nucl. Med. Mol. Imag. 30 (2003): 1338-1347.
• [7] Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., von Guggenberg, E., Bale R., and Virgolini, I.J., “68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med.” 48 (2007): 508–518.
• [8] Schuhmacher, J. and Maier, B.W., “A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HCl. ” Int. J. Appl. Radiat. Isot. 32 (1981): 31–36.
• [9] Decristoforo, C., Knopp, R., von Guggenberg, E., Rupprich, M., Reger, T., Hess, A., Virgolini, I. and Haubner, R., “A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl. Med. Commun.” 28 (2007): 870–875.
• [10] Meyer, G.J.,. Maecke, H.,. Schuhmacher, J, Knapp, W.H and Hofmann, M. “68Ga-labelled DOTA-derivatised peptide ligands.” Eur. J. Nucl. Med. Mol. Imaging 31 (2004): 1097–1104.